In the long human struggle against cancer, a technology forged in pandemic urgency is now being turned toward one of medicine's oldest adversaries. Moderna announced it will present late-breaking data on its mRNA cancer vaccine at the European Society for Medical Oncology Congress in 2026, sending its stock to new highs and signaling that the same molecular platform that helped the world through COVID-19 may be finding a second, more enduring purpose. The moment is less a declaration of victory than an invitation to scrutiny — a promising chapter in a story that science has been trying to writ